The management of coronary patients scheduled for a coronary artery bypass grafting
(CABG), who are receiving one or more antiplatelet drugs, is plenty of controversies. It has …

In the absence of well-defined recommendations deriving from prospective randomized
clinical trials, the perioperative management of antiplatelet therapy should be based on the …

Background and objectiveBleeding after cardiac surgery correlates with morbidity and
mortality. The aim of this study was to determine the influence of antiplatelet therapy on …

Background: Antiplatelet therapy is critical in the management of coronary artery disease.
For patients undergoing coronary artery bypass graft surgery (CABG), controversy remains …

OBJECTIVES The purpose of this multicentre cohort study was to examine the relationship
between antiplatelet therapy (APT) at the time of coronary artery bypass grafting (CABG) and …

Widespread adoption of the antiplatelet agents into everyday clinical practice has
revolutionized contemporary care of the cardiovascular patient. Major adverse …

Performing a surgical procedure on a patient undergoing anti-platelet therapy raises a
dilemma: is it safer to withdraw the drugs and reduce the haemorrhagic risk, or to maintain …

Antiplatelet therapy is widely accepted in the contemporary management of patients with
coronary syndromes. Effective platelet inhibition can cause an increased risk of bleeding …

Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing
surgery still remains poorly defined and a matter of debate among cardiologists, surgeons …

BACKGROUND: Cardiovascular complications are important causes of morbidity and
mortality in patients undergoing elective non-cardiac surgery, with adverse cardiac …